Entecavir as a P2X7R antagonist ameliorates platelet activation and thrombus formation.

Platelet activation is the primary cause of thrombosis. The P2X7 receptor (P2X7R) is a therapeutic target of thrombosis. However, it is still unknown whether P2X7R activation affects platelet thrombus.